Top-Searched Lab Tests
Explore Conditions
Explore Biomarkers
Explore Diagnostic Labs
New Lab Tests
| Test Name | Methodology | Specimen | TAT | Lab |
|---|---|---|---|---|
| MI Cancer Seek® | NGS | Tumor Tissue, Tissue | 14 d | Caris Life Sciences |
| PD-L1 22C3 FDA for NSCLC | Immunoassay | Tissue | 1-2 d | NeoGenomics |
| PD-L1 22C3 FDA (KEYTRUDA®) for Cervical | Immunoassay | Tissue | 1-2 d | NeoGenomics |
| PD-L1 22C3 FDA (KEYTRUDA®) for HNSCC (Head & Neck) | Immunoassay | Tissue | 1-2 d | NeoGenomics |
| PD-L1 28-8 (OPDIVO®) for Gastric/GEJ/EAC | Immunoassay | Tissue | 1-2 d | NeoGenomics |
MI Cancer Seek®
Methodology:NGS
Specimen:Tumor Tissue, Tissue
TAT:14 d
Lab:Caris Life Sciences
PD-L1 22C3 FDA for NSCLC
Methodology:Immunoassay
Specimen:Tissue
TAT:1-2 d
Lab:NeoGenomics
PD-L1 22C3 FDA (KEYTRUDA®) for Cervical
Methodology:Immunoassay
Specimen:Tissue
TAT:1-2 d
Lab:NeoGenomics
PD-L1 22C3 FDA (KEYTRUDA®) for HNSCC (Head & Neck)
Methodology:Immunoassay
Specimen:Tissue
TAT:1-2 d
Lab:NeoGenomics
PD-L1 28-8 (OPDIVO®) for Gastric/GEJ/EAC
Methodology:Immunoassay
Specimen:Tissue
TAT:1-2 d
Lab:NeoGenomics
Featured Companion Diagnostics
| Test Name | Methodology | Specimen | TAT | Lab |
|---|---|---|---|---|
| xT CDx | NGS | Tissue, Whole Blood, Saliva | 10-14 d | Tempus AI |
| Vysis Chronic Lymphocytic Leukemia (CLL) Panel | Chromosomal / Cytogenetics | Whole Blood, Bone Marrow | 5 d | MPLN |
| PD-L1 SP263 FDA for NSCLC | Immunoassay | Tissue | 1-2 d | NeoGenomics |
| PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) | Chromosomal / Cytogenetics | Tumor Tissue | — | ARUP Laboratories |
| nAbCyte™ Anti‑AAVRh74var HB‑FE Assay (nAbCyte Assay) | Other | Serum | 7-10 d | Labcorp |
xT CDx
Methodology:NGS
Specimen:Tissue, Whole Blood, Saliva
TAT:10-14 d
Lab:Tempus AI
Vysis Chronic Lymphocytic Leukemia (CLL) Panel
Methodology:Chromosomal / Cytogenetics
Specimen:Whole Blood, Bone Marrow
TAT:5 d
Lab:MPLN
PD-L1 SP263 FDA for NSCLC
Methodology:Immunoassay
Specimen:Tissue
TAT:1-2 d
Lab:NeoGenomics
PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD)
Methodology:Chromosomal / Cytogenetics
Specimen:Tumor Tissue
TAT:—
Lab:ARUP Laboratories
nAbCyte™ Anti‑AAVRh74var HB‑FE Assay (nAbCyte Assay)
Methodology:Other
Specimen:Serum
TAT:7-10 d
Lab:Labcorp
Featured Sponsored Testing
| Program Name | Therapeutic Area(s) | Condition | Lab |
|---|---|---|---|
| NovoDETECT Primary Hyperoxaluria Panel | Nephrology | Primary Hyperoxaluria (PH) | Blueprint Genetics |
| Invitae Skeletal Disorders Panel | Musculoskeletal | Skeletal Dysplasias | Invitae | Labcorp |
| Color Hereditary Cancer Test | Oncology | Ovarian Cancer, Uterine/Endometrial Cancer | Color Health |
| FCSNext | Endocrinology | Familial Chylomicronemia Syndrome (FCS) | Ambry Genetics |
| Gaucher Disease and ASMD (Niemann-Pick A/B) | Metabolic | Gaucher Disease, Acid Sphingomyelinase (ASM) Deficiency (Niemann-Pick Disease Type A and B) | Revvity Omics, Inc. |
NovoDETECT Primary Hyperoxaluria Panel
Therapeutic Area(s):Nephrology
Condition:Primary Hyperoxaluria (PH)
Lab:Blueprint Genetics
Invitae Skeletal Disorders Panel
Therapeutic Area(s):Musculoskeletal
Condition:Skeletal Dysplasias
Lab:Invitae | Labcorp
Color Hereditary Cancer Test
Therapeutic Area(s):Oncology
Condition:Ovarian Cancer, Uterine/Endometrial Cancer
Lab:Color Health
FCSNext
Therapeutic Area(s):Endocrinology
Condition:Familial Chylomicronemia Syndrome (FCS)
Lab:Ambry Genetics
Gaucher Disease and ASMD (Niemann-Pick A/B)
Therapeutic Area(s):Metabolic
Condition:Gaucher Disease, Acid Sphingomyelinase (ASM) Deficiency (Niemann-Pick Disease Type A and B)
Lab:Revvity Omics, Inc.











